Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side-viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7-36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1-(9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [57]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Self-citationGlucagon-like peptide-1, a new hormone of the entero-insular axis
Ørskov, C. (1992) · Diabetologia · doi:10.1007/bf00429088 · Cited by 293
Structure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282
New developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Dipeptidyl peptidase IV, a kidney brush-border serine peptidase
Kenny, A. J., Booth, A. G., George, S. G., Ingram, J., Kershaw, D., Wood, E. J., & Young, A. R. (1976) · Biochemical Journal · doi:10.1042/bj1570169 · Cited by 254
Cited by
Items 401–500 of 798
Glucagon-like peptide 1 (GLP-1) and metabolic diseases
Rotella, C. M., Pala, L., & Mannucci, E. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03347560 · Cited by 36
Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold
Cheon, H. G., Kim, S. S., Kim, K.-R., Rhee, S.-D., Yang, S., Ahn, J. H., Park, S.-D., Lee, J., Jung, W. H., Lee, H. S., et al. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.04.004 · Cited by 32
Sakashita, H., Akahoshi, F., Yoshida, T., Kitajima, H., Hayashi, Y., Ishii, S., Takashina, Y., Tsutsumiuchi, R., & Ono, S. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.059 · Cited by 30
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
Mulvihill, E. E. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000495 · Cited by 29
“However, levels of GLP-1 in circulation are 96 www.co-lipidology.com very low, owing to degradation by the serine protease dipeptidyl peptidase 4 (DPP4) [17].”
BackgroundInfluentialImmunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut
Morrow, N. M., Morissette, A., & Mulvihill, E. E. (2024) · Peptides · doi:10.1016/j.peptides.2024.171200 · Cited by 34
“The serine protease, dipeptidyl peptidase 4 (DPP4), rapidly inactivates the two peptides by cleaving two amino acids from the N-terminal [12 – 14].”
Liu, H., Xiao, H., Lin, S., Zhou, H., Cheng, Y., Xie, B., & Xu, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372399 · Cited by 41
Ren, L., Cui, Q., Liu, W., Wang, L., Liao, Y., Feng, Y., Sun, W., Yang, Y., Zhang, Z., Jin, T., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00930 · Cited by 31
Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs
He, H., Tran, P., Yin, H., Smith, H. T., Flood, D., Kramp, R., Filipeck, R., Fischer, V., & Howard, D. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023002 · Cited by 30
“…peptide-1 (GLP-1) activity, which in turn produces a clinically significant lowering of diabetic glycemia comparable with that observed when GLP-1 is administered by direct infusion (Gutniak et al., 1992, 1997; Deacon et al., 1995; Mentlein, 1999; Drucker, 2003; Mest and Mentlein, 2005).”
BackgroundExendin-4, a GLP-1 Receptor Agonist, Modulates the Effect of Macronutrients on Food Intake by Rats
Aziz, A. A., & Anderson, G. H. (2002) · Journal of Nutrition · doi:10.1093/jn/132.5.990 · Cited by 32
“The latter observations may be due to the short half-life of GLP-1 in rodents because dipeptidyl-peptidase IV (DPPIV), an enzyme present in capillaries surrounding intestinal cells, in the liver as well as in the circulation rapidly catabolizes the peptide (18,19).”
BackgroundLee, Y. S., Riopel, M., Cabrales, P., & Bandyopadhyay, G. K. (2019) · Science Advances · doi:10.1126/sciadv.aaw4176 · Cited by 33
“Once released, circulating incretins are rapidly inactivated by the specific peptidase enzyme dipeptidyl peptidase-4 (DPP4) (10) and are eventually cleared, mainly by the kidney (11).”
Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies
Bayanati, M., Rabbani, M. I. M., Kabiri, S. S., Sadegh, B. M. M., Rezaee, E., & Tabatabai, S. A. (2024) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-151581 · Cited by 37
Gardiner, S., March, J., Kemp, P., Bennett, T., & Baker, D. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00867.x · Cited by 28
“Release of GLP-1(7–36) in response to feeding is extremely rapid, but circulating levels then quickly fall (halflife 1–2 min), mainly due to enzymatic cleavage of the two N-terminal amino acids by dipeptidyl peptidase 4 (DPP-4), to form GLP-1(9–36) (Deacon et al., 1995).”
BackgroundTsuchimochi, W., Ueno, H., Yamashita, E., Tsubouchi, C., Sakoda, H., Nakamura, S., & Nakazato, M. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0393 · Cited by 31
“Active GLP-1[736]NH2 and active GIP[1-42] were measured using the Glucagon Like Peptide-1 (Active) ELISA kit (Millipore, St.”
BackgroundMethodAhlkvist, L., Brown, K., & Åhrén, B. (2013) · Endocrine Connections · doi:10.1530/ec-12-0079 · Cited by 31
Incretin therapy for diabetes mellitus type 2
Holst, J. J. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000516 · Cited by 32
“The discovery of this inactivation [44] lead to the proposal that inhibition of the DPP-4 enzyme might be useful in diabetes therapy [45], and indeed this turned out to be the case, as first demonstrated experimentally [46] and subsequently in clinical studies [47].”
ResultSelf-citationWang, X., Yang, W., Hölscher, C., Wang, Z., Cai, H., Li, Q., & Qi, J. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23181 · Cited by 32
“Because the natural GLP-1 can be rapidly degraded by the enzyme DPP IV (Deacon et al., 1995), Val(8)-GLP-1(7–36), a GLP-1 analogue with profound resistance to DPP IV and greater biological activity (Green et al.”
BackgroundMethodSathananthan, M., Farrugia, L. P., Miles, J. M., Piccinini, F., Dalla Man, C., Zinsmeister, A. R., Cobelli, C., Rizza, R. A., & Vella, A. (2013) · Diabetes · doi:10.2337/db13-0140 · Cited by 28
“This enzyme is widely distributed so that the half-life of active GLP-1 in the circulation is;1 min (2).”
BackgroundDeng, X., Li, H., Zhou, J., Zhang, H., & Li, Q. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.10.010 · Cited by 30
Derosa, G., & Maffioli, P. (2011) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s16361 · Cited by 27
“This observation suggests resistance to the action of GIP, making GLP-1 the favored potential therapeutic target.(8) Because GLP-1 is rapidly degraded by DPP-4,(9) a new class of compounds have been developed: DPP-4 inhibitors, that delay endogenous degradation of GLP-1 and GIP.”
BackgroundIncretin-based therapies: can we achieve glycemic control and cardioprotection?
Angeli, F. S., & Shannon, R. P. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0195 · Cited by 30
“The native peptide (GLP-1 (7–36) amide) is rapidly cleavage by the dipeptidyl peptidase 4 (DPP-4) enzyme (Deacon et al. 1995), limiting circulating half-life and subsequent biological effects on pancreatic b cells.”
BackgroundSavignano, F. A., Crajoinas, R. O., Pacheco, B. P. M., Campos, L. C. G., Shimizu, M. H. M., Seguro, A. C., & Girardi, A. C. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.054 · Cited by 31
Non-insulin anti-diabetic drugs: An update on pharmacological interactions
Ruscica, M., Baldessin, L., Boccia, D., Racagni, G., & Mitro, N. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.005 · Cited by 32
Are peptide conjugates the golden therapy against obesity?
Brandt, S. J., Kleinert, M., Tschöp, M. H., & Müller, T. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0264 · Cited by 27
Exenatide: a novel treatment of Type 2 diabetes
Åhrén, B. (2005) · Therapy · doi:10.2217/14750708.2.2.207 · Cited by 26
Åhrén, B., Winzell, M. S., Burkey, B. F., & Hughes, T. E. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.08.019 · Cited by 29
“GLP-1 is cleaved by the enzyme dipeptidyl peptidase-IV (DPP-4) (Deacon et al., 1995; (Mentlein, 1999).”
O'Harte, F. P. M., Mooney, M., Kelly, C., McKillop, A. M., & Flatt, P. R. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00125-7 · Cited by 28
On the Treatment of Diabetes Mellitus with Glucagon‐like Peptide‐1
Holst, J. J., Deacon, C. F., TOFT‐NIELSEN, M., & Knudsen, L. B. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb11193.x · Cited by 30
“34 However, in this case it also seems that a considerable degradation is occurring, again requiring modifications of the peptide to stabilize it against DPP-IV.”
BackgroundSelf-citationGLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
“dase-4 (DPP4), degrades the peptides (31), and”
BackgroundDIPEPTIDYL PEPTIDASE-IV INHIBITORY ACTIVITY OF SOME INDONESIAN MEDICINAL PLANTS
Riyanti, S., Suganda, A. G., & Sukandar, E. Y. (2016) · Asian Journal of Pharmaceutical and Clinical Research · Cited by 26
Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
Kang, S. M., & Park, J. H. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211051698 · Cited by 37
“21,22 Rather, GLP-1 (9-36) and GLP-1 (28-36) are cleaved from GLP-1 by DPP-4; they exert beneficial cardiovascular functions, such as improving left ventricular function, vasodilation, and improving intrahepatic lipid metabolism.”
BackgroundInfluentialEmerging GLP-1 receptor agonists
Lund, A., Knop, F. K., & Vilsbøll, T. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.616493 · Cited by 26
“One of the major challenges in developing GLP-1-based therapy is that native GLP-1 is very rapidly degraded in the circulation by the enzyme dipeptidyl peptidase 4 (DPP-4), which cleaves off the two N-terminal amino acids and leaves the molecule inactive with regard to insulin secretion [17], resulting in a half-life…”
BackgroundIncretins in patients with rheumatoid arthritis
Segura, B. T., López‐Mejías, R., Domínguez‐Luis, M. J., de Vera-González, A. M., Delgado, A. G., Ubilla, B., Olmos, J. M., Hernández, J. L., González-Gay, M. Á., & Ferraz‐Amaro, I. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1431-9 · Cited by 29
“Several studies have confirmed that DPP-4-mediated inactivation of these peptides is a critical control mechanism for regulating the biological activity of both GIP and GLP-1 in vivo in humans [4].”
BackgroundGallwitz, B. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.651 · Cited by 26
Human colon produces fully processed glucagon‐like peptide‐1 (7–36) amide
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00983-g · Cited by 24
Self-citationKusunoki, Y., Katsuno, T., Myojin, M., Miyakoshi, K., Ikawa, T., Matsuo, T., Ochi, F., Tokuda, M., Murai, K., Miuchi, M., et al. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0290 · Cited by 27
Desheng, L., Gao, J., Yuanhua, C., Cui, W., Zhang, H., & Ji, M. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.093 · Cited by 28
Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV
Hansen, L., Hare, K. J., Hartmann, B., Deacon, C. F., Ugleholdt, R., Plamboeck, A., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.08.012 · Cited by 27
Self-citationPET of Glucagonlike Peptide Receptor Upregulation After Myocardial Ischemia or Reperfusion Injury
Gao, H., Kiesewetter, D. O., Zhang, X., Huang, X., Guo, N., Lang, L., Hida, N., Wang, H., Wang, H., Cao, F., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109413 · Cited by 27
“After acute myocardial infarction, an increased inotropic effect was noted in patients receiving GLP-1(7-36) amide infusion for up to 3 d after successful reperfusion (32).”
BackgroundGong, Q., Rajagopalan, S., & Zhong, J. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.06.076 · Cited by 32
“Subsequent studies confirmed the metabolism of GLP-1 and GIP mediated by DPP4 did indeed occur in vivo [99,102].”
BackgroundLong-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus
Vilsbøll, T., & Knop, F. K. (2008) · BioDrugs · doi:10.2165/00063030-200822040-00004 · Cited by 25
“[3] Although GLP-1 (DPP-4),[12] which removes the two N-terminal amino acids and is more potent than GIP, GIP circulates at higher levels, with the renders the molecules inactive with respect to insulin secretion.[13]”
Siegel, Scharf, Gallwitz, Mentlein, Morys‐Wortmann, Fölsch, & Schmidt (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00440.x · Cited by 24
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 38
Glucagon‐like peptide‐2: A potential role in equine insulin dysregulation
de Laat, M. A., Fitzgerald, D. M., Sillence, M. N., & Spence, R. J. (2018) · Equine Veterinary Journal · doi:10.1111/evj.12825 · Cited by 24
“It is uncertain why a higher GLP-2 concentration was measured, but may be related to peptide degradation by the enzyme dipeptidyl peptidase IV (DPPIV).”
BackgroundGhrelin regulates GLP-1 production through mTOR signaling in L cells
Xu, G., Hong, X., Tang, H. W., Jiang, S., Liu, F., Shen, Z., Li, Z., & Zhang, W. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.08.016 · Cited by 25
“The majority of circulating biologically active GLP-1 is found in the GLP-1 (7e36) amide form (Deacon et al., 1995).”
BackgroundSitagliptin: A novel agent for the management of type 2 diabetes mellitus
Pham, D. Q., Nogid, A., & Plakogiannis, R. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070248 · Cited by 28
Exenatide once weekly: clinical outcomes and patient satisfaction
Tahrani, A. A., Jose, B., Piya, M. K., & Barnett, A. H. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s7494 · Cited by 29
“Incretins are rapidly metabolized by the enzyme DPP-4, and thus have extremely short half-lives (GIP , 2 minutes and GLP-1 5–7 minutes).(42,43) The short half-life of these naturally occurring incretins limited their clinical use.”
The interplay between leptin, glucocorticoids, and GLP1 regulates food intake and feeding behaviour
Perez‐Leighton, C. E., Kerr, B., Scherer, P. E., Baudrand, R., & Cortés, V. (2023) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.13039 · Cited by 27
“…Wettergren et al ., 1998) but its mean plasma half-life is approximately only 3 min due to its degradation by dipeptidyl peptidase IV (DPP-IV) and removal by the kidneys (Meier et al ., 2004; Deacon, Johnsen & Holst, 1995; Kieffer, McIntosh & Pederson, 1995; Mentlein, Gallwitz & Schmidt, 1993).”
BackgroundGLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
“logic conditions (102, 103).”
Understanding the Cardiovascular Effects of Incretin
Yoon, J. S., & Lee, H. W. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.5.437 · Cited by 26
“Approximately 80% of the circulating active GLP-1 is GLP-1 (7-36) amide, which is rapidly cleaved by dipeptidyl peptidase-4 (DPP-4) to GLP-1 (9-36), which does not interact with the known GLP-1 receptor [6,10,11].”
BackgroundWang, Z., Wang, X., Zhang, L., Wang, B., Xu, B., & Zhang, J. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107495 · Cited by 24
Molecular Pharmacology of the Incretin Receptors
Al‐Sabah, S. (2015) · Medical Principles and Practice · doi:10.1159/000433437 · Cited by 26
Zhang, Q., Qu, Li, Hovgaard, L., Li, Wang, J., Zhang, X., & Zhang, Q. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30013 · Cited by 23
“5 To overcome those drawbacks, some efforts have been made, such as the development of metabolically stable analogs of GLP-1 6,7 and the use of enzyme inhibitors.”
Albiglutide: a unique GLP-1 receptor agonist
Rendell, M. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1240780 · Cited by 23
“GLP-1 is rapidly degraded in the circulation by the enzyme dipeptidyl peptidase-4 (DPP-4) which cleaves off the two NH2terminal amino acids [12].”
BackgroundBöhm, A., Wagner, R. J., Machicao, F. E., Holst, J. J., Gallwitz, B., Stefan, N., Fritsche, A., Häring, H., & Staiger, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181880 · Cited by 25
“Total GLP-1 and GIP levels (in pmol/L, both) were quantified using radioimmunoassays specific for the C-terminal parts of the peptides [19,20].”
MethodSelf-citationBukrinski, J. T., Sønderby, P., Antunes, F., Andersen, B., Schmidt, E. G. W., Peters, G. H. J., & Harris, P. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00492 · Cited by 27
“Furthermore, a specific inactivation mechanism exists as GLP-1 is sensitive to dipeptidyl-peptidase-IV (DPP-IV) hydrolysis and is therefore rapidly inactivated in human plasma by truncation of the N-terminal His-Ala forming the inactive 9-36-amide degradation product 10 .”
BackgroundAlbrechtsen, N. J. W., Mark, P., Terzic, D., Hansen, L. H., Andersen, U. Ø., Hartmann, B., Carr, R. D., Gustafsson, F., Deacon, C. F., Holst, J. J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00515 · Cited by 26
Self-citationGaggini, M., Sabatino, L., Suman, A. F., Chatzianagnostou, K., & Vassalle, C. (2025) · Cells · doi:10.3390/cells14050387 · Cited by 35
Li, Y., Vaughan, K. L., Tweedie, D., Jung, Y. J., Kim, H. K., Choi, H.-I., Kim, D. S., Mattison, J. A., & Greig, N. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-53356-2 · Cited by 24
The effect of gum chewing on blood GLP-1 concentration in fasted, healthy, non-obese men
Xu, J., Xiao, X., Li, Y., Zheng, J., Li, W., Zhang, Q., & Wang, Z. (2015) · Endocrine · doi:10.1007/s12020-015-0566-1 · Cited by 22
Heard, K. R., Wu, W., Li, Y., Zhao, P., Woźnica, I., Lai, J. H.-S., Beinborn, M., Sanford, D. G., DiMare, M. T., Chiluwal, A. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400423p · Cited by 26
New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar, M. (2011) · PubMed · Cited by 29
Wu, T., Rayner, C. K., & Horowitz, M. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0164 · Cited by 24
Unique binding mode of Evogliptin with human dipeptidyl peptidase IV
Lee, H. K., Kim, M., Kim, H. D., Kim, H. J., Kim, J. W., Lee, J., Kim, C., & Kim, E. E. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.101 · Cited by 22
Natural Triterpenoids for the Treatment of Diabetes Mellitus: A Review
Lyu, H., Chen, J., & Li, W. (2016) · Natural Product Communications · doi:10.1177/1934578x1601101037 · Cited by 23
Sharma, A., Paliwal, G., Upadhyay, N., & Tiwari, A. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0143-4 · Cited by 28
“making them biologically inactive [77].”
RetractedPromising New Approaches to the Management of Obesity
Mertens, I. L., & Gaal, L. F. V. (2000) · Drugs · doi:10.2165/00003495-200060010-00001 · Cited by 24
“GLP-1 are very short-lived, since it is metabolised very quickly by the dipeptidyl-peptidase IV (DPPIV) enzyme.[40] DPP-IV, or CD 26, seems to play a role in many physiological processes such as in immune, inflammatory and endocrine responses.”
BackgroundBär, J. W., Weber, A., Hoffmann, T., Stork, J., Wermann, M., Wagner, L., Aust, S., Gerhartz, B., & Demuth, H. (2003) · Biological Chemistry · doi:10.1515/bc.2003.172 · Cited by 22
“These gastrointestinal hormones stimulate the glucose-dependent insulin secretion (Deacon et al., 1995; Mentlein, 1999), inhibit glucagon re- Joachim Bär, Anja Weber, Torsten Hoffmann*, Jörg Stork, Michael Wermann, Leona Wagner, Susanne Aust, Bernd Gerhartza and Hans-Ulrich Demuth Probiodrug AG,…”
BackgroundNäslund, E. B., Skogar, S., Efendić, S., & Hellström, P. M. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00054-x · Cited by 25
Li, H., Wang, H., Schegg, K. M., & Schooley, D. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13463 · Cited by 21
HOLST, J. J., TOFT-NIELSEN, M.-B., ØRSKOV, C., NAUCK, M., & WILLMS, B. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17549.x · Cited by 21
Self-citationBioanalytical Approaches to Assess The Proteolytic Stability of Therapeutic Fusion Proteins
Pearson, J. T., & Rock, D. A. (2015) · Bioanalysis · doi:10.4155/bio.15.217 · Cited by 21
Nakamura, K., Fukunishi, S., Yokohama, K., Ohama, H., Tsuchimoto, Y., Asai, A., Tsuda, Y., & Higuchi, K. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2899 · Cited by 21
“The actions of GLP-1 in vivo are short-lived due to their rapid degradation and inactivation by the enzyme dipeptidyl peptidase-4 (DPP-4) (7,8).”
Akhtar, N., Jafri, L., Green, B. D., Kalsoom, S., & Mirza, B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01376 · Cited by 23
“One of them is glucagon-like peptide 1 (GLP1) and other is glucose dependent-insulinotropic polypeptide (GIP; Deacon et al., 1995).”
BackgroundDay, S. M., Yang, W., Wang, X., Stern, J. E., Zhou, X., Macauley, S. L., & Ma, T. (2019) · eneuro · doi:10.1523/eneuro.0031-19.2019 · Cited by 21
“Circulating GLP-1 (7-36) is rapidly degraded (half-life 2 min) into GLP-1 (9-36) by dipeptidyl peptidase-4 (Deacon et al., 1995; Hansen et al., 1999; Nikolaidis et al., 2005).”
BackgroundForbes, S., Moonan, M., Robinson, S., Anyaoku, V., Patterson, M., Murphy, K. G., Ghatei, M. A., Bloom, S. R., & Johnston, D. G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02172.x · Cited by 26
Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli
Yin, X., Wei, D., Yi, L., Tao, X., & Ma, Y. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2004.10.014 · Cited by 21
Hedetoft, C., Sheikh, S. P., Larsen, S. U., & Holst, J. J. (2000) · Pancreas · doi:10.1097/00006676-200001000-00004 · Cited by 22
Self-citationNeuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 30
GLP-1 receptor agonists in the context of cancer: the road ahead
Miousse, I. R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00245.2025 · Cited by 23
Hill, T. G., & Hill, D. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074070 · Cited by 26
“…relevance in contributing to the paracrine stimulation of GSIS postprandially, this is unlikely to mostly derive from the intestinal L-cells, since circulating GLP-1 has a short biological half-life of a couple of minutes as a result of degradation by dipeptidyl peptidase 4 (DPP-4) [72].”
BackgroundGiragossian, C., Vage, C., Li, J., Pelletier, K. B., Piche‐Nicholas, N., Rajadhyaksha, M., Liras, J. L., Logan, A., Calle, R. A., & Weng, Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061713 · Cited by 21
“In vitro serum stability generally tends to underestimate in vivo CL for biologics (Pauwels et al., 1985; Deacon et al., 1995; Hartmann et al., 2000).”
BackgroundCirculating glucagon-like peptide-1 increases in response to short-term overfeeding in men
Wadden, D., Cahill, F., Amini, P., Randell, E. W., Vasdev, S., Yi, Y., Church, J. G., & Sun, G. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-33 · Cited by 23
“Active GLP-1 has a very short half-life and is found in low concentrations, before it is degraded by DPP-IV, while total GLP-1 gives an indication of the secretion from intestinal L-cells.”
BackgroundWu, T., Zhang, X., Trahair, L. G., Bound, M. J., Little, T. J., Deacon, C. F., Horowitz, M., Jones, K. L., & Rayner, C. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2813 · Cited by 21
“Notably, both GIP and GLP-1 undergo rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) (13, 14).”
BackgroundSelf-citationSaeed, K. M., Shah, S. A., Ullah, R., Alam, S. I., Park, J. S., Saleem, S., Jo, M. H., Kim, M. W., Hahm, J. R., & Kim, M. O. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9523758 · Cited by 24
“Previously, we have reported that quinovic acid and its glycoside derivatives have been shown to have strong inhibitory activity against dipeptidyl peptidase-4 (DPP-4) [41], which is an important enzyme involved in cleaving various neuropeptides and incretin hormones possessing antiinflammatory activity [46].”
BackgroundRetractedPractical combination therapy based on pathophysiology of type 2 diabetes
LEVIN, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s109216 · Cited by 22
“It is estimated that the half-life of biologically active GLP-1 in circulation is less than 2 minutes because of rapid degradation by DPP-4 activity.(56,57) By inhibiting the DPP-4 enzyme and thereby increasing the half-life of endogenous incretin hormones in circulation, DPP-4 inhibitors i ndirectly increase stimulat…”
Senmaru, T., Fukui, M., Kobayashi, K., Iwase, H., Inada, S., Okada, H., Asano, M., Yamazaki, M., Hasegawa, G., Nakamura, N., et al. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00220.x · Cited by 20
Plamboeck, A., Holst, J. J., Carr, R. D., & Deacon, C. F. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47920-6_36 · Cited by 23
Self-citationDanilova, O. V., Tai, A., Mele, D. A., Beinborn, M., Leiter, A. B., Greenberg, A. S., Perfield, J. W., DeFuria, J., Singru, P. S., Lechan, R. M., et al. (2009) · Endocrinology · doi:10.1210/en.2009-0386 · Cited by 20
“Frozen sections of small intestine (1,2), pancreas (3,4), and liver (5,6) were immunolabeled, using FITC-conjugated anti-GFP antiserum (1, 3, and 5, phase contrast; 2, 4, and 6, immunofluorescence).”
BackgroundMethodNew therapies for type 2 diabetes based on glucagon-like peptide 1.
Salehi, M., & D’Alessio, D. A. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.4.382 · Cited by 23
Chou, J. Z., Place, G. D., Waters, D. G., Kirkwood, J. A., & Bowsher, R. R. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9700560 · Cited by 19
Understanding peptide hormones: from precursor proteins to bioactive molecules
Voilquin, L., Wiggenhorn, A. L., & Svensson, K. J. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.03.014 · Cited by 20
Shao, Y., Yuan, G., Feng, Y., Zhang, J., & Guo, X. (2014) · Peptides · doi:10.1016/j.peptides.2013.11.011 · Cited by 22
Yu, X., Fridman, A., Bagchi, A., Xu, S. S., Kwasnjuk, K., Lu, P., & Cancilla, M. T. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00652 · Cited by 17
Vivanco-Maroto, S. M., Santos-Hernández, M., Sanchón, J., Picariello, G., Recio, I., & Miralles, B. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111238 · Cited by 21
Egholm, C., Khammy, M. M., Dalsgaard, T., Mazur, A., Tritsaris, K., Hansen, A. J., Aalkjær, C., & Dissing, S. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00316.2016 · Cited by 19
“Time (min) [C a 2 + ] i n M VEGFA GLP-1(1-36) +VEGFA”
BackgroundMethodInfluentialKim, D.-M., Chu, S.-H., Kim, S., Park, Y.-W., & Kim, S.-S. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.4.212 · Cited by 18
“ever, its very short half-life, which is primarily caused by degradation by DPP-IV, inhibits its clinical application (15-17).”
BackgroundMa, X., Hui, H., Liu, Z., He, G., Hu, J. R., Meng, J., Guan, L., & Luo, X. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01070.x · Cited by 18
Parker, J. C., Lavery, K. S., Irwin, N., Green, B., Greer, B., Harriott, P., O'Harte, F. P. M., Gault, V. A., & Flatt, P. R. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06904 · Cited by 18
“Similarly, 60% of the circulating GLP-1 exist as the major metabolite, GLP-1(9–36)amide (Deacon et al. 1995).”
Background
Metadata
- Authors
- Deacon, C. F., Johnsen, A. H., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-03
- Volume
- 80
- Issue
- 3
- Pages
- 952-957
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2068183831
- Cited by
- 792
- References
- 28
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 24 · 2023: 10 · 2022: 14 · 2021: 24 · 2020: 18 · 2019: 34 · 2018: 25 · 2017: 37 · 2016: 41 · 2015: 22 · 2014: 27 · 2013: 40 · 2012: 42
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- glucagon-like peptide-1, dipeptidyl peptidase IV, human plasma, peptide metabolism, endogenous metabolites
- MeSH terms
- Chromatography, High Pressure Liquid, Female, Glucagon, Humans, Male, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.